Shanghai Shenqi Medical Technology and Shanghai Bio‑heart Biological Technology (HKG: 2185) entered into a strategic partnership to jointly advance the commercialization and clinical application of Bio‑heart’s proprietary BioHeart Bioresorbable Sirolimus‑Eluting Coronary Stent System (the “BioHeart Stent“), a new‑generation bioresorbable sirolimus‑eluting coronary stent featuring an ultra‑thin strut design with a minimum thickness of 90μm.
Partnership Snapshot
| Item | Detail |
|---|---|
| Parties | Shanghai Shenqi Medical and Shanghai Bio-heart Biological Technology (HKG: 2185) |
| Announcement Date | 22 Sep 2026 |
| Agreement Type | Strategic partnership for commercialization and clinical application |
| Product | BioHeart Bioresorbable Sirolimus-Eluting Coronary Stent System (BioHeart Stent) |
| Partner Contributions | Innovative medical device R&D, sales channel development, and academic promotion – each leveraging its respective strengths |
| Financial Terms | Not disclosed in the announcement |
Product Profile – BioHeart Stent
- Modality: A new‑generation bioresorbable sirolimus‑eluting coronary stent system independently developed by Bio‑heart.
- Strut Design: Features an ultra‑thin strut design with a minimum thickness of 90μm – a profile engineered to improve device performance in complex coronary anatomy.
- Deliverability: The thin‑strut architecture enhances deliverability and lesion crossability, easing navigation through tortuous and tightly stenosed vessels during percutaneous coronary intervention (PCI).
- Mechanical Integrity: The design maintains structural radial strength despite the reduced strut thickness, addressing the historical trade‑off between thin struts and scaffold support in bioresorbable platforms.
- Drug Elution: Sirolimus elution provides localized antiproliferative therapy to suppress neointimal hyperplasia and reduce in‑stent restenosis.
- Bioresorbable Advantage: As a bioresorbable scaffold, the system is designed to be absorbed over time, restoring natural vessel physiology and vasomotion after the healing phase – a differentiator versus permanent metallic drug‑eluting stents.
Commercialization Strategy
- Channel Development: The partners will combine strengths in sales channel development to build market access for the BioHeart Stent across interventional cardiology centers.
- Academic Promotion: Joint academic promotion activities are planned to support clinical adoption, physician education, and evidence dissemination in coronary intervention.
- R&D Collaboration: Continued cooperation in innovative medical device R&D supports platform iteration beyond the initial stent system.
- Regulatory and Launch Status: Approval status, launch timing, and pricing for the BioHeart Stent – not disclosed in the announcement.
Market Impact & Outlook
- China Coronary Device Landscape: Coronary stents remain a high‑volume PCI consumable in China; a bioresorbable sirolimus‑eluting platform with a 90μm ultra‑thin strut positions Bio‑heart in the premium, next‑generation segment differentiated from conventional metallic DES.
- Structural Differentiation: Balancing deliverability and radial strength at a 90μm minimum thickness directly targets the key limitations that constrained earlier bioresorbable scaffold generations, potentially improving physician acceptance.
- Go‑to‑Market Leverage: Shenqi Medical’s channel and academic capabilities complement Bio‑heart’s device R&D base, creating a vertically integrated commercialization pathway for the listed company (HKG: 2185).
- Catalysts Ahead: Regulatory clearances, clinical study readouts, and hospital listing progress for the BioHeart Stent will be the key milestones to watch.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding partnership execution, product commercialization timelines, clinical adoption, and market performance of the BioHeart Stent. Actual results may differ materially due to risks including regulatory approvals, competitive dynamics, reimbursement policies, and clinical outcomes.-Fineline Info & Tech
